Latest period
$3.77B
YoY change
+7.3%
5Y CAGR
+17.4%
Peak year (2025)
$18.56B
Latest annual
$18.56B
Operating Cash Flow history chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: $18.56B
Operating Cash Flow growth chart for Novo Nordisk (NVO) from 1990 to 2025
Latest: +7.3%
Operating Cash Flow history table for Novo Nordisk (NVO) from 1990 to 2025
| 2025 | $18.56B | +7.3% | +$1.27B | ||
| 2024 | $17.30B | +10.0% | +$1.58B | ||
| 2023 | $15.72B | +45.0% | +$4.88B | ||
| 2022 | $10.84B | +28.2% | +$2.38B | ||
| 2021 | $8.46B | +1.5% | +$128.27M | ||
| 2020 | $8.33B | +20.1% | +$1.39B | ||
| 2019 | $6.93B | +1.6% | +$112.36M | ||
| 2018 | $6.82B | +4.7% | +$306.58M | ||
| 2017 | $6.51B | -6.9% | −$486.39M | ||
| 2016 | $7.00B | +24.6% | +$1.38B | ||
| 2015 | $5.62B | +5.7% | +$302.61M | ||
| 2014 | $5.32B | +12.3% | +$582.46M | ||
| 2013 | $4.74B | +22.5% | +$870.99M | ||
| 2012 | $3.86B | -0.2% | −$6.43M | ||
| 2011 | $3.87B | +8.0% | +$286.15M | ||
| 2010 | $3.58B | +17.5% | +$533.53M | ||
| 2009 | $3.05B | +33.5% | +$766.06M | ||
| 2008 | $2.29B | +17.6% | +$342.79M | ||
| 2007 | $1.94B | +45.0% | +$602.81M | ||
| 2006 | $1.34B | -3.4% | −$47.60M | ||
| 2005 | $1.39B | +3.9% | +$51.43M | ||
| 2004 | $1.34B | +30.6% | +$313.32M | ||
| 2003 | $1.02B | — | — | ||
| 2002 | — | — | — | ||
| 2001 | — | — | — | ||
| 2000 | — | — | — | ||
| 1999 | — | — | — | ||
| 1998 | — | — | — | ||
| 1997 | — | — | — | ||
| 1996 | — | — | — | ||
| 1995 | — | — | — | ||
| 1994 | — | — | — | ||
| 1993 | — | — | — | ||
| 1992 | — | — | — | ||
| 1991 | — | — | — | ||
| 1990 | — | — | — |
- 2025$18.56B+7.3%
- 2024$17.30B+10.0%
- 2023$15.72B+45.0%
- 2022$10.84B+28.2%
- 2021$8.46B+1.5%
- 2020$8.33B+20.1%
- 2019$6.93B+1.6%
- 2018$6.82B+4.7%
- 2017$6.51B-6.9%
- 2016$7.00B+24.6%
- 2015$5.62B+5.7%
- 2014$5.32B+12.3%
- 2013$4.74B+22.5%
- 2012$3.86B-0.2%
- 2011$3.87B+8.0%
- 2010$3.58B+17.5%
- 2009$3.05B+33.5%
- 2008$2.29B+17.6%
- 2007$1.94B+45.0%
- 2006$1.34B-3.4%
- 2005$1.39B+3.9%
- 2004$1.34B+30.6%
- 2003$1.02B—
- 2002——
- 2001——
- 2000——
- 1999——
- 1998——
- 1997——
- 1996——
- 1995——
- 1994——
- 1993——
- 1992——
- 1991——
- 1990——
Operating Cash Flow values are taken from Novo Nordisk's reported cash flow statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts converted to USD using IAS 21 average exchange rates (P&L / cash flow) or closing rates (balance sheet). Originally filed in DKK.
About Operating Cash Flow at Novo Nordisk (NVO)
Operating Cash Flow for Novo Nordisk (NVO): headline value $3.77B · YoY +7.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual operating cash flow for Novo Nordisk (NVO) came in at 119.10B DKK – edged down 1.5% year-over-year.
Across 2020–2025 (5 years), Novo Nordisk operating cash flow produced a CAGR of +18.0% – with mixed annual results across the window.
Between 2024 and 2025, Novo Nordisk operating cash flow edged down 1.5%, falling from 120.97B DKK to 119.10B DKK.
The highest annual operating cash flow of 120.97B DKK was reported in 2024. The lowest in the available history was 1.19B DKK in 1991.
Novo Nordisk Operating Cash Flow by Year
Novo Nordisk Operating Cash Flow 2025: $18.56B
In 2025, Novo Nordisk reported operating cash flow of 119.10B DKK ($18.56B), edged down 1.5% below 2024.
Novo Nordisk Operating Cash Flow 2024: $17.30B
Novo Nordisk operating cash flow in 2024 was 120.97B DKK ($17.30B), grew 11.1% from 2023. This figure represents the highest annual value in the available history.
Novo Nordisk Operating Cash Flow 2023: $15.72B
2023's operating cash flow for Novo Nordisk came in at 108.91B DKK ($15.72B), surged 38.1% from 2022.
Novo Nordisk Operating Cash Flow 2022: $10.84B
Novo Nordisk posted operating cash flow of 78.89B DKK ($10.84B) in 2022, surged 43.4% from 2021.
Novo Nordisk Operating Cash Flow 2021: $8.46B
Novo Nordisk operating cash flow in 2021 was 55.00B DKK ($8.46B).
See more financial history for Novo Nordisk (NVO).
Sector peers by Operating Cash Flow
Healthcare peers of Novo Nordisk (NVO), ranked by their latest operating cash flow
| $24.53B | |
| $19.70B | |
| $19.03B | |
| $16.81B | |
| $16.47B | |
| $14.57B | |
| $9.96B | |
| $7.82B |
- $24.53B
- $19.70B
- $19.03B
- $16.81B
- $16.47B
- $14.57B
- $9.96B
Frequently asked questions
Novo Nordisk (NVO) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation